|
Gene: TWSG1 |
Gene summary for TWSG1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TWSG1 | Gene ID | 57045 |
Gene name | twisted gastrulation BMP signaling modulator 1 | |
Gene Alias | TSG | |
Cytomap | 18p11.22 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | Q9GZX9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57045 | TWSG1 | P61T-E | Human | Esophagus | ESCC | 3.44e-77 | 2.84e+00 | 0.099 |
57045 | TWSG1 | P62T-E | Human | Esophagus | ESCC | 1.12e-26 | 5.69e-01 | 0.1302 |
57045 | TWSG1 | P65T-E | Human | Esophagus | ESCC | 6.40e-07 | 2.08e-02 | 0.0978 |
57045 | TWSG1 | P74T-E | Human | Esophagus | ESCC | 6.02e-22 | 6.03e-01 | 0.1479 |
57045 | TWSG1 | P75T-E | Human | Esophagus | ESCC | 1.23e-12 | 1.45e-01 | 0.1125 |
57045 | TWSG1 | P76T-E | Human | Esophagus | ESCC | 1.46e-15 | 7.42e-02 | 0.1207 |
57045 | TWSG1 | P79T-E | Human | Esophagus | ESCC | 8.42e-12 | 2.80e-01 | 0.1154 |
57045 | TWSG1 | P80T-E | Human | Esophagus | ESCC | 1.91e-16 | 3.32e-01 | 0.155 |
57045 | TWSG1 | P83T-E | Human | Esophagus | ESCC | 2.63e-10 | 1.31e-01 | 0.1738 |
57045 | TWSG1 | P107T-E | Human | Esophagus | ESCC | 1.07e-17 | 5.58e-01 | 0.171 |
57045 | TWSG1 | P127T-E | Human | Esophagus | ESCC | 2.64e-07 | 1.40e-01 | 0.0826 |
57045 | TWSG1 | P128T-E | Human | Esophagus | ESCC | 3.78e-28 | 9.48e-01 | 0.1241 |
57045 | TWSG1 | P130T-E | Human | Esophagus | ESCC | 2.19e-52 | 1.28e+00 | 0.1676 |
57045 | TWSG1 | C04 | Human | Oral cavity | OSCC | 6.09e-13 | 1.02e+00 | 0.2633 |
57045 | TWSG1 | C21 | Human | Oral cavity | OSCC | 4.30e-19 | 8.57e-01 | 0.2678 |
57045 | TWSG1 | C30 | Human | Oral cavity | OSCC | 1.88e-14 | 1.02e+00 | 0.3055 |
57045 | TWSG1 | C38 | Human | Oral cavity | OSCC | 1.24e-05 | 9.27e-01 | 0.172 |
57045 | TWSG1 | C43 | Human | Oral cavity | OSCC | 1.66e-12 | 3.05e-01 | 0.1704 |
57045 | TWSG1 | C46 | Human | Oral cavity | OSCC | 5.60e-05 | 3.47e-01 | 0.1673 |
57045 | TWSG1 | C08 | Human | Oral cavity | OSCC | 4.28e-29 | 6.59e-01 | 0.1919 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:00715599 | Esophagus | ESCC | response to transforming growth factor beta | 157/8552 | 256/18723 | 2.95e-07 | 4.23e-06 | 157 |
GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
GO:00715609 | Esophagus | ESCC | cellular response to transforming growth factor beta stimulus | 151/8552 | 250/18723 | 1.78e-06 | 2.10e-05 | 151 |
GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
GO:002261216 | Esophagus | ESCC | gland morphogenesis | 78/8552 | 118/18723 | 5.83e-06 | 6.03e-05 | 78 |
GO:00071799 | Esophagus | ESCC | transforming growth factor beta receptor signaling pathway | 121/8552 | 198/18723 | 8.26e-06 | 8.03e-05 | 121 |
GO:00017044 | Esophagus | ESCC | formation of primary germ layer | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
GO:000268316 | Esophagus | ESCC | negative regulation of immune system process | 231/8552 | 434/18723 | 8.48e-04 | 4.36e-03 | 231 |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:00456675 | Esophagus | ESCC | regulation of osteoblast differentiation | 77/8552 | 132/18723 | 2.28e-03 | 1.00e-02 | 77 |
GO:000715918 | Esophagus | ESCC | leukocyte cell-cell adhesion | 192/8552 | 371/18723 | 1.03e-02 | 3.51e-02 | 192 |
GO:190303717 | Esophagus | ESCC | regulation of leukocyte cell-cell adhesion | 174/8552 | 336/18723 | 1.36e-02 | 4.43e-02 | 174 |
GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
GO:00715598 | Oral cavity | OSCC | response to transforming growth factor beta | 140/7305 | 256/18723 | 2.34e-07 | 3.70e-06 | 140 |
GO:00715608 | Oral cavity | OSCC | cellular response to transforming growth factor beta stimulus | 137/7305 | 250/18723 | 2.68e-07 | 4.15e-06 | 137 |
Page: 1 2 3 4 5 6 7 8 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TWSG1 | SNV | Missense_Mutation | c.155A>T | p.Asn52Ile | p.N52I | Q9GZX9 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TWSG1 | SNV | Missense_Mutation | c.331G>C | p.Asp111His | p.D111H | Q9GZX9 | protein_coding | tolerated(0.08) | benign(0.05) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TWSG1 | deletion | Frame_Shift_Del | novel | c.534delN | p.His179IlefsTer41 | p.H179Ifs*41 | Q9GZX9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TWSG1 | SNV | Missense_Mutation | rs376720221 | c.226N>G | p.Met76Val | p.M76V | Q9GZX9 | protein_coding | deleterious(0.01) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TWSG1 | SNV | Missense_Mutation | c.521N>G | p.Asp174Gly | p.D174G | Q9GZX9 | protein_coding | deleterious(0.01) | benign(0.233) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TWSG1 | SNV | Missense_Mutation | c.307N>A | p.Leu103Ile | p.L103I | Q9GZX9 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
TWSG1 | SNV | Missense_Mutation | c.251N>T | p.Asp84Val | p.D84V | Q9GZX9 | protein_coding | deleterious(0.03) | possibly_damaging(0.494) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TWSG1 | SNV | Missense_Mutation | c.454N>G | p.Ser152Gly | p.S152G | Q9GZX9 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
TWSG1 | SNV | Missense_Mutation | novel | c.393G>T | p.Glu131Asp | p.E131D | Q9GZX9 | protein_coding | tolerated(0.13) | benign(0.424) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TWSG1 | SNV | Missense_Mutation | c.325N>C | p.Glu109Gln | p.E109Q | Q9GZX9 | protein_coding | deleterious(0.01) | benign(0.054) | TCGA-CI-6620-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Ancillary | leucovorin | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |